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Abstract
Background: Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on
different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials
of anti-psoriasis agents. The recombinant humanized IgG1 monoclonal antibody efalizumab targets multiple T-cell-
dependent steps in the immunopathogenesis of psoriasis. Efalizumab has demonstrated safety and efficacy in
several clinical trials, and improves patients' quality of life. Objective: To evaluate the impact of efalizumab on
HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis, including a
large cohort of High-Need patients for whom at least 2 other systemic therapies were unsuitable because of lack
of efficacy, intolerance, or contraindication.
Methods: A total of 793 patients were randomized in a 2:1 ratio to receive efalizumab 1 mg/kg/wk (n = 529) or
placebo (n = 264) for 12 weeks. The study population included 526 High-Need patients (342 efalizumab, 184
placebo). The treatment was evaluated by patients using the HRQOL assessment tools Short Form-36 (SF-36)
and Dermatology Life Quality Index (DLQI). Other patient-reported assessments included the Psoriasis Symptom
Assessment (PSA), a visual analog scale (VAS) for itching, and the Patient's Global Psoriasis Assessment (PGPA).
Results: Efalizumab was associated with improvements at Week 12 from baseline in patient-reported outcomes,
both in the total study population and in the High-Need cohort. Among all efalizumab-treated patients, the DLQI
improved by 5.7 points from baseline to Week 12, relative to an improvement of 2.3 points for placebo patients
(P < .001). Corresponding improvements in DLQI in the High-Need cohort were 5.4 points for efalizumab
compared to 2.3 for placebo (P < .001). Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS
at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.
Conclusion: A 12-week course of efalizumab improved HRQOL and other patient-reported outcomes in
patients with moderate to severe plaque psoriasis. The benefits of efalizumab therapy in High-Need patients were
similar to those observed in the total study population, indicating that the beneficial impact of efalizumab on QOL
is consistent regardless of disease severity, prior therapy, or contraindications to previous therapies.
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Background
Psoriasis is an incurable, chronic, immune-mediated dis-
ease. The impact of psoriasis on patients' physical, social,
and psychological functioning and health-related quality
of life (HRQOL) has been well documented [1-4]. Many
patients report moderate to extreme feelings of anxiety,
anger, and depression [5]. Increasing severity of psoriasis
appears to correlate closely with increased severity of
depression and, in turn, with higher frequency of suicidal
ideation [6,7]. However, disease severity as measured by
instruments such as the Psoriasis Area and Severity Index
(PASI) is not the sole factor determining the burden of ill-
ness, because relatively minor psoriasis located on visible
parts of the body may also have a detrimental effect on
HRQOL [8].
Quality-of-life indicators and traditional physician-
assessed clinical outcomes are correlated only weakly in
psoriasis, suggesting that they measure separate, comple-
mentary aspects of the disease's impact [9,10]. Thus,
assessment of HRQOL during clinical trials is important
for establishing the overall impact of an investigational
anti-psoriasis agent as well as its likelihood of acceptance
by the psoriatic population [11].
The negative impact of psoriasis on patients' HRQOL is
compounded by side effects and toxicities associated with
many current systemic psoriasis treatments – which may
also increase the need for laboratory monitoring – and
inconvenient administration regimens. Such issues high-
light the need for new therapies that provide greater
safety, efficacy, and convenience than those currently
available. An improved understanding of the critical role
of the immune system, in particular that of T cells, in the
pathogenesis of psoriasis has provided the impetus for the
development of biological agents that target particular
steps in the immunopathogenesis of the disease [12].
Efalizumab is a humanized monoclonal antibody that
blocks multiple T-cell-dependent functions implicated in
the pathogenesis of psoriasis [13]. Multiple placebo-con-
trolled Phase III clinical studies have assessed the safety
and efficacy of efalizumab therapy in patients with mod-
erate to severe chronic plaque psoriasis. These studies
demonstrated a favorable safety profile as well as efficacy
versus placebo according to physician-assessed measures,
such as improvement from baseline in PASI [14-19]. Fur-
thermore, in these trials, efalizumab was associated with
significantly greater improvements from baseline versus
placebo in all patient-reported outcome measures, includ-
ing improvements in HRQOL as measured by instruments
such as the Dermatology Life Quality Index (DLQI) [20].
The international Phase III trial (the Clinical Experience
Acquired with Raptiva®  [CLEAR] study) evaluated the
safety and efficacy of efalizumab in patients with moder-
ate to severe plaque psoriasis, including a large cohort of
High-Need patients, defined as those for whom at least 2
other systemic therapies were unsuitable because of lack
of efficacy, intolerance, or contraindication. As reported
elsewhere, efalizumab treatment was associated with sig-
nificant improvements versus placebo in physician-
assessed outcome measures and demonstrated a favorable
safety profile over 12 weeks of therapy (Dubertret L, Sterry
W, Bos JD, et al., unpublished data.) The effects of efalizu-
mab on HRQOL and other patient-reported outcomes in
the first 12-week treatment period of this trial are
described here.
Methods
Study design
This Phase III multiphase, randomized, double-blind,
placebo-controlled, parallel-group multicenter trial was
conducted to evaluate the safety and efficacy of weekly
efalizumab compared with placebo in patients with mod-
erate to severe plaque psoriasis. During the study period,
but before results were available, a protocol amendment
restricted enrollment to patients meeting the definition of
"High-Need" patients (Dubertret L, Sterry W, Bos JD, et al.,
unpublished data). High-Need patients were subjectively
defined as those for whom 2 or more current systemic
therapies (e.g., photochemotherapy [PUVA],
cyclosporine, corticosteroids, methotrexate, oral retin-
oids, mycophenolate mofetil, thioguanine, hydroxyurea,
sirolimus, azathioprine, 6-mercaptopurine) were ineffec-
tive, poorly tolerated, or contraindicated.
During the initial 12-week treatment period, eligible
patients were randomized in a 2:1 ratio to receive either
efalizumab 1 mg/kg (Raptiva®, Genentech, Inc.) or match-
ing placebo, administered subcutaneously once weekly
for 12 weeks (Dubertret L, Sterry W, Bos JD, et al., unpub-
lished data). Patients were initially randomized between
March 12, 2003, and June 3, 2003; following the protocol
amendment, patients were randomized between July 16,
2003, and September 30, 2003. A conditioning dose of
0.7 mg/kg was administered on Day 0; subsequent doses
were administered at 1 mg/kg. Systemic therapies for pso-
riasis were discontinued at least 28 days before treatment
initiation, and topical therapies were discontinued 14
days before treatment initiation. Other systemic psoriasis
therapies or phototherapy were not permitted during the
trial. Emollients and tar or salicylic acid preparations for
scalp lesions and small quantities of group VI or VII topi-
cal corticosteroids for lesions on the face, hands, feet,
groin, or axillae were permitted, but these medications
were not to be used on the day of a scheduled PASI assess-
ment.BMC Dermatology 2005, 5:13 http://www.biomedcentral.com/1471-5945/5/13
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A total of 104 clinical centers in Europe, Russia, Israel,
Australia, Mexico, and Canada participated in this trial.
The relevant ethics committee at each participating study
center reviewed and approved the study protocol, and all
patients provided written informed consent before under-
going the screening procedures.
Patients
Initially, entry criteria for this study were similar to those
of previous efalizumab Phase III trials [14-18]. All
patients enrolled were 18 to 75 years of age with at least a
6-month history of plaque psoriasis, with involvement of
≥10% of total body surface area (BSA), had a minimum
PASI of 12.0 at screening, and had received previous sys-
temic treatment for psoriasis or were treatment-naïve can-
didates for such therapy. Patients experiencing clinically
significant disease flare at screening or enrollment were
excluded, as were patients with a major concomitant ill-
ness, immune disorder, or organ dysfunction. During the
study, a protocol amendment was introduced that
restricted enrollment to patients meeting the High-Need
criteria (defined above).
Patient-reported outcome assessments
The effect of efalizumab on quality of life in patients with
moderate to severe plaque psoriasis was assessed using 2
HRQOL instruments: a general health questionnaire (the
Short Form-36 [SF-36]) and a validated, self-adminis-
tered, dermatology-specific questionnaire (the DLQI).
Patients evaluated psoriasis symptoms using the Psoriasis
Symptom Assessment (PSA) and an itching visual analog
scale (VAS). In addition, patients evaluated the overall
severity of their psoriasis using the Patient's Global Psoria-
sis Assessment (PGPA). Patient-reported outcome assess-
ments were performed at baseline and Weeks 4, 8, and 12.
The SF-36 is a multipurpose health survey that measures
functional health and well-being in 8 dimensions: Mental
Health (psychological distress and well-being), Pain
(bodily pain), Physical Functioning (limitations in physi-
cal activities because of health problems), Role Emotional
(limitations in usual activities because of emotional prob-
lems), Role Physical (limitations in usual activities
because of physical problems), Social (limitations in
social activities because of physical or emotional prob-
lems), Vitality (energy or fatigue), and General Health
Perceptions [21]. Scores for each dimension range from 0
to 100, with higher scores representing better quality of
life. The 8 subscales can be combined to produce 2 sum-
mary measures, called the Physical Health and Mental
Health scores. The Physical Health score is the sum of the
subscale scores for Physical Function, Role Physical, Pain,
and General Health Perceptions; and the Mental Health
score is the sum of the subscale scores for Vitality, Social,
Role Emotional, and General Mental Health. The Physical
Health and Mental Health scores can therefore range from
0 to 400, with higher scores representing better health per-
ceptions. An overall summary score is also produced,
which consists of the sum of all the subscale scores (pos-
sible scores range from 0 to 800).
The DLQI is a reliable, validated 10-item questionnaire
covering 6 dimensions (symptoms and feelings, daily
activities, leisure, work and school, personal relation-
ships, and treatment) that assesses the overall impact of
skin disorders and current treatments on the patient's
functioning and well-being [22]. Each question has 4 pos-
sible responses, with lower scores representing a better
quality of life.
The PSA is a psoriasis-specific questionnaire derived from
the symptom scale of the Skindex-29, a validated skin dis-
order instrument [23], consisting of a 16-item patient-
reported measure of 8 psoriasis-related cutaneous symp-
toms: pain, burning or stinging, itching, bothered by
water, irritation, sensitivity, bleeding, and scaling. The fre-
quency and severity of each symptom over the preceding
2 weeks are reported on a scale from 0 to 3, corresponding
to categories ranging from "never" to "always," respec-
tively, for frequency, and "not at all" to "a great deal" for
severity. Individual scores are summed to give the values
of the 2 PSA component subscales that evaluate overall
frequency and severity of disease symptoms, with lower
scores representing less frequent or less severe psoriasis
symptoms.
The itching scale used in this study measures the severity
of itching at a specific point in time, using a horizontal
VAS. Possible scores range from 0 (no itching) to 10
(severe itching).
The PGPA consists of a single self-explanatory item to be
completed by the patient, evaluating overall cutaneous
disease at a specific point in time, with possible scores
ranging from 0 (no psoriasis) to 10 (worst psoriasis imag-
inable).
Statistical analyses
This study was designed to evaluate the efficacy and safety
of efalizumab compared to placebo in patients with mod-
erate to severe plaque psoriasis. A protocol amendment
introduced assessment of efficacy and safety in the High-
Need cohort as well as the total study population, chang-
ing entry criteria to ensure enrollment of sufficient High-
Need patients. The same amendment added an interim
analysis to determine efficacy in the originally defined
study population and to verify that the study had ade-
quate power to detect relevant treatment differences in the
High-Need population, using the primary endpoint ofBMC Dermatology 2005, 5:13 http://www.biomedcentral.com/1471-5945/5/13
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PASI-75 (Dubertret L, Sterry W, Bos JD, et al., unpublished
data).
The intent-to-treat population, consisting of all rand-
omized patients who received at least 1 dose, was the pri-
mary population for all efficacy analyses, including
patient-reported outcomes. For patients missing a Week
12 value, the last observed value was carried forward to
impute missing data (last observation carried forward
imputation). Statistical analyses on continuous parame-
ters were performed using analysis of variance (ANOVA)
on raw data, adjusting for baseline PASI (≤16.0, ≥16.1),
previous use of systemic treatment for psoriasis (yes or
no), and geographical region. Analyses were performed
on transformed data (e.g., log transformed or ranked) if
assumptions of normality were not satisfied. Patients were
Mean improvement from baseline in Short Form-36 components at Week 12 in the total (A) and High-Need (B) study popula- tions Figure 1
Mean improvement from baseline in Short Form-36 components at Week 12 in the total (A) and High-Need (B) study popula-
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included in analyses of patient-reported outcomes only if
questionnaires were completed with sufficient informa-
tion to calculate the scores and improvements from base-
line. The SF-36 and DLQI were not evaluated in patients
from centers where appropriate validated translations of
the questionnaire were unavailable (the Czech Republic,
Greece, Portugal, and Russia for the SF-36; Greece, Israel,
Portugal, and Russia for the DLQI).
Results
Patient disposition
A total of 793 patients with moderate to severe plaque
psoriasis were randomized and received at least 1 dose of
efalizumab (n = 529) or placebo (n = 264). The study
population included a High-Need cohort of 526 patients,
of whom 342 were randomized to efalizumab and 184 to
placebo. Demographic and baseline disease characteris-
tics were comparable between treatment groups in both
the High-Need cohort and the total study population, as
previously described (Dubertret L, Sterry W, Bos JD, et al.,
unpublished data).
Patient-reported measures of HRQOL
Short Form-36
At Week 12, efalizumab-treated patients showed signifi-
cantly greater improvements from baseline than did pla-
cebo patients (P ≤ .05) in each SF-36 component except
for the Physical Functioning Index (Figure 1A). It should
be noted that the baseline scores for the Physical Func-
tioning Index were highest among all the SF-36 dimen-
sions for all patients (mean ± SD = 77.8 ± 25.3, as
compared to a mean ± SD range from low to high of 55.3
± 20.5 for Vitality Index to 64.7 ± 40.9 for Role Physical).
The high baseline score for the Physical Functioning Index
indicates that impairment of quality of life was not as
large on this dimension as compared to the other dimen-
sions. The greatest differences in improvement associated
with efalizumab therapy compared to placebo were in the
domains that measure role limitations due to physical
and emotional health, the Role Physical (10.1 points for
efalizumab vs. -4.5 points for placebo; P < .001) and Role
Emotional (12.2 points efalizumab vs. 0.7 points placebo,
P = .005) dimensions. The SF-36 overall summary score
improved by 59.7 points for patients receiving efalizumab
versus 10.4 points for patients receiving placebo (P  =
.002). As in the total population analysis, efalizumab-
treated High-Need patients demonstrated greater mean
improvements from baseline than placebo patients in all
SF-36 dimensions, except for the Physical Functioning
Index, with the greatest difference in improvement in the
Role Physical (10.9 vs -3.4, respectively, P = .004) and
Role Emotional domains (11.7 points vs 2.5 points,
respectively, P = .004; Figure 1B). Overall, efalizumab-
treated High-Need patients demonstrated significantly
greater improvement from baseline compared to placebo
in the SF-36 summary score (57.3 points efalizumab vs.
19.7 points placebo, P = .039).
Dermatology Life Quality Index
At Week 12, patients in the efalizumab group demon-
strated a significantly greater improvement from baseline
in DLQI total score compared with placebo patients (5.7
points vs. 2.3 points, respectively; P < .001) (Figure 2A).
Patients receiving efalizumab had greater improvements
from baseline relative to placebo in all 6 dimensions of
the DLQI, with the largest improvement observed in the
Symptoms and Feelings dimension (1.6 points for efalizu-
mab vs. 0.7 points for placebo). Improvement from base-
line in DLQI total score was significantly greater for
efalizumab than placebo as early as Week 4 (P < .001).
Results at Week 12 were similar between the High-Need
cohort and the total study population, with efalizumab-
treated patients achieving significantly greater improve-
ment than placebo-treated patients in DLQI total score
(5.4 points vs 2.3 points, respectively, P < .001; Figure
2B). Greater improvements from baseline were evident for
efalizumab-treated patients compared to placebo-treated
patients for all individual components of the DLQI. As
observed in the total study population, in the High-Need
cohort, improvement from baseline in DLQI total score
was significantly greater with efalizumab compared to
placebo as early as Week 4 (P < .001). Further, the largest
improvement in the High-Need patients was observed in
the Symptoms and Feelings dimension and was identical
to that observed in the total study population (Figure 2B).
Psoriasis Symptom Assessment
At Week 12, improvements in the PSA Frequency and
Severity scores in the total study population were signifi-
cantly greater for patients in the efalizumab group com-
pared to the placebo group. PSA Frequency had improved
by 5.7 points in efalizumab-treated patients versus 2.0
points for placebo-treated patients, and PSA Severity had
improved by 6.2 points in the efalizumab group versus
1.9 in the placebo group (P < .001 for both analyses; Table
1). A significant difference between treatments was
observed as early as Week 4 (P < .001). Results for the
High-Need cohort were comparable to those observed in
the total study population (Table 1). High-Need efalizu-
mab-treated patients achieved significantly greater
improvement than placebo-treated patients in the PSA
Frequency (5.8 points vs 2.1 points, P < .001) and PSA
Severity (6.3 points vs 1.9 points, P < .001) scores (Table
1).
Itching Visual Analog Scale
In the total study population, the mean itching VAS score
had improved from baseline by 2.5 points from baseline
at Week 12 in efalizumab-treated patients, compared to
0.6 points for placebo-treated patients (P < .001; Table 1).BMC Dermatology 2005, 5:13 http://www.biomedcentral.com/1471-5945/5/13
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A significant difference between treatment groups in
mean improvement from baseline was observed as early
as Week 4 (P < .001). As in the total study population,
efalizumab patients in the High-Need cohort demon-
strated significantly greater improvement than placebo
patients from baseline at Week 12 (2.4 points vs 0.4
points, P < .001; Table 1) with significant improvement
noted as early as Week 4 (P < .001).
Patient's Global Psoriasis Assessment
In the total study population, greater mean improvements
from baseline were observed in efalizumab-treated
Mean improvement from baseline in Dermatology Life Quality Index components at Week 12 in the total (A) and High-Need  (B) study populations Figure 2
Mean improvement from baseline in Dermatology Life Quality Index components at Week 12 in the total (A) and High-Need 
(B) study populations.BMC Dermatology 2005, 5:13 http://www.biomedcentral.com/1471-5945/5/13
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patients compared to placebo-treated patients at Week 12
(2.8 points efalizumab vs. 0.4 points placebo, P < .001;
Table 1). Identical improvements were observed in the
High-Need cohort (Table 1).
Safety and tolerability
The safety profile of the 12-week course of efalizumab in
this trial is reported elsewhere (Dubertret L, Sterry W, Bos
JD, et al., unpublished data). Briefly, adverse events were
generally mild to moderate in severity and were similar
between the total study population and the High-Need
cohort. In the total study population, the most frequently
reported adverse events (≥5% of patients in either treat-
ment group) were headache (reported in 26.1% of efalizu-
mab vs. 14.0% of placebo patients), "influenza-like
illness" (9.6% vs. 7.2%), arthralgia (7.4% vs. 3.0%), rigors
(6.2% vs. 5.3%), pyrexia (7.9% vs. 1.1%), nasopharyngi-
tis (5.3% vs. 4.2%), myalgia (5.5% vs. 2.7%), and pruritus
(3.6% vs. 5.7%). Serious adverse events were reported in
5.5% of efalizumab-treated patients and 3.4% of placebo
patients in the total study population. Adverse events led
to withdrawal in 5.7% of efalizumab and 2.7% of placebo
patients.
Discussion
This randomized, placebo-controlled trial of efalizumab
in patients with moderate to severe plaque psoriasis is the
first to evaluate the impact of a psoriasis therapy on
patient-reported outcomes in a large cohort of prospec-
tively, but subjectively, defined High-Need patients.
Enrollment of High-Need patients allowed assessment of
a new treatment option for a patient group that can be
particularly challenging to clinicians.
In this study, 12 weeks of efalizumab treatment resulted
in significant improvements in multiple patient-reported
outcomes including 2 HRQOL instruments (SF-36 and
DLQI) and patient-reported efficacy measures (PSA, itch-
ing VAS, and PGPA), in both the total study population
and the High-Need cohort. These results confirm and
extend findings reported from several Phase III efalizu-
mab trials [20]. Importantly, results for the CLEAR trial's
High-Need cohort, a difficult-to-treat population, demon-
strated similar improvements to those seen in the broader
group of moderate to severe psoriasis patients and in pre-
vious efalizumab studies [20]. Improvements from base-
line in PSA Frequency, PSA Severity, itching VAS, and
PGPA were statistically significantly greater for efalizu-
mab-treated High-Need patients than for placebo-treated
High-Need patients. Collectively, these results suggest
that, as assessed by the patients themselves, efalizumab
treatment results in improvements in multiple aspects of
psoriasis symptoms, including the severity and frequency
of pruritus, pain, bleeding, scaling, and irritation, and in
the impact of these symptoms on patients' daily lives and
mental health.
Efalizumab-treated High-Need patients achieved signifi-
cantly greater overall quality-of-life improvement than
placebo-treated patients as measured by all individual
components of the dermatology-specific DLQI and in
most SF-36 dimensions. With the exception of the Role
Physical dimension (measuring role limitations due to
physical health), treatment differences in the individual
dimensions were not statistically significant for the High-
Need population. The reduction in evaluable patients for
the SF-36 (and DLQI) due to absence of validated ques-
tionnaires in some countries might have contributed to
the absence of statistically significant differences in SF-36
components between treatment groups in the High-Need
cohort. The significant effect of efalizumab treatment on
physical functioning indicates the negative impact psoria-
sis has on a patient's physical abilities as they relate to the
frequency at which physical activities are performed; thus
Role Physical is well suited for evaluating an aspect of
patient QOL that is impacted by psoriasis.
Recent critical review of the DLQI and SF-36 quality-of-
life measures for validity and internal consistency has
demonstrated high reproducibility and internal consist-
Table 1: Mean improvement from baseline at Week 12 for patient-reported clinical outcome measures in the total study population 
and the High-Need cohort.
PSA Itching VAS PGPA
Patient Population n Frequency Mean Severity Mean n Mean n Mean
High-Need Cohort
Placebo 184 2.1 1.9 184 0.4 182 0.4
Efalizumab 340 5.8* 6.3* 339 2.4* 341 2.8*
Total Population
Placebo 262 2.0 1.9 261 0.6 261 0.4
Efalizumab 527 5.7* 6.2* 526 2.5* 528 2.8*
*P < .001 versus placebo.
PSA, Psoriasis Symptom Assessment; VAS, Visual Analog Scale; PGPA, Patient's Global Psoriasis Assessment.BMC Dermatology 2005, 5:13 http://www.biomedcentral.com/1471-5945/5/13
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ency scores for both scales [24]; however, the relationship
to a clinical meaningful response requires further analysis.
A previous analysis of patient-reported outcome measures
including the DLQI, PSA, and 2 itch scales from 2 rand-
omized clinical trials of efalizumab demonstrated signifi-
cant correlation with 2 measures of clinical outcome, PASI
and Overall Lesion Severity (OLS) scores [25]. More
recently, the clinical relevance of improvement in QOL
was evaluated in a pooled analysis of 4 Phase III, rand-
omized, double-blind, placebo-controlled studies of efal-
izumab (Finlay, et al., unpublished results presented at
the 3rd EADV Spring Symposium, Sofia, Bulgaria, May
19–22, 2005). The analysis employed a minimal clinically
important difference (MCID) that was defined as a change
in DLQI of ≥5 points [26]; 57% of efalizumab-treated
patients achieved MCID after 12 weeks of therapy com-
pared with 29% of placebo-treated patients. Under these
criteria for MCID, the mean improvement in DLQI for the
total study population and High-Need cohort indicates
achievement of MCID in the present study.
A mean Physical Functioning Index of 84.2 was found
from a general US population [27], supporting the con-
clusion that the baseline score for our study (77.8) was
already near the maximum score typically observed. The
relatively high patient scores for the Physical Functioning
Index at baseline compared to the other SF-36 dimensions
suggest that this dimension may not be particularly sensi-
tive to the aspects of HRQOL affected by psoriasis. These
findings demonstrate the importance of assessing quality
of life in psoriasis using a combination of a general instru-
ment and a dermatology-specific instrument [28].
Together, the results from the SF-36 and the DLQI demon-
strate that efalizumab treatment results in improvements
in both physical and mental aspects of HRQOL in both
the total study population and the High-Need cohort.
Systemic psoriasis therapies, such as methotrexate,
cyclosporine, acitretin, and psoralen-ultraviolet A (PUVA)
phototherapy, are efficacious in improving PASI and
HRQOL with short-term use [10,29]. However, these
agents are associated with toxicities or contraindications
that may limit their long-term use and make them unsuit-
able for many patients [30-33]. With efalizumab, rapid
and significant improvements in HRQOL and in physi-
cian-assessed (Dubertret L, Sterry W, Bos JD, et al., unpub-
lished data) and patient-assessed efficacy measures were
observed in the High-Need cohort of this study, for whom
several other systemic agents were not viable treatment
options. The safety profile was similar between the High-
Need cohort and the total study population and was con-
sistent with that observed in previous Phase III rand-
omized efalizumab studies [14-18]. Furthermore, results
from an open-label Phase III study of up to 36 months of
continuous efalizumab therapy in psoriasis suggest that
the efficacy and safety profiles of efalizumab are main-
tained during extended treatment (Leonardi CL, et al.,
unpublished data). Three-year safety and efficacy data are
particularly important considering that current guidelines
recommend against continuous use of cyclosporine and
recommend periodic liver biopsies with continued meth-
otrexate use [31,33]. The significant improvements
achieved by High-Need patients in the present study,
combined with the favorable safety profile demonstrated
in this cohort, suggest that efalizumab therapy may fulfill
the need for a viable therapeutic option in this patient
population.
Conclusion
In summary, these results demonstrate that efalizumab
provided significant patient-reported improvements in
HRQOL, in terms of both the frequency and severity of
psoriasis symptoms and their impact on the patient's
daily life and sense of well-being. These improvements
were observed in both the total study population of
patients with moderate to severe plaque psoriasis and the
High-Need cohort for whom other systemic therapies
were unsuitable. The HRQOL findings support and rein-
force the findings of efficacy according to physician-
assessed measures such as the PASI (Dubertret L, Sterry W,
Bos JD, et al., unpublished data). Moreover, a favorable
safety profile was demonstrated in both study popula-
tions. Given the negative impact that psoriasis can have
on HRQOL, these are important findings. The results indi-
cate that the beneficial impact of efalizumab on QOL is
consistent regardless of disease severity, prior therapy, or
contraindications to previous therapies and are particu-
larly encouraging as they suggest the possibility of effec-
tive treatment in High-Need, or difficult-to-treat, patients
who have few viable treatment options.
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